Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Becaris Publishing Limited
2023-08-01
|
| Col·lecció: | Journal of Comparative Effectiveness Research |
| Matèries: | |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|